Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Atogepant: First Approval.

Literature DB >> 34813050

Atogepant: First Approval.

Abstract

Atogepant (Qulipta™) is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for the prophylaxis of migraine. In September 2021, atogepant was approved in the USA for the preventive treatment of episodic migraine in adults. The drug is also in phase 3 clinical development for the preventive treatment of migraine in various other countries. This article summarizes the milestones in the development of atogepant leading to this first approval for the preventive treatment of episodic migraine in adults.

Entities: Chemical

Mesh：

Substances：

Year: 2022 PMID： 34813050 DOI： 10.1007/s40265-021-01644-5

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

2 in total

1. T2* reduction in patients with acute post-traumatic headache.

Authors: Simona Nikolova; Todd J Schwedt; Jing Li; Teresa Wu; Gina M Dumkrieger; Katherine B Ross; Visar Berisha; Catherine D Chong
Journal: Cephalalgia Date: 2021-10-13 Impact factor: 6.292

Review 2. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.

Authors: Tessa de Vries; Carlos M Villalón; Antoinette MaassenVanDenBrink
Journal: Pharmacol Ther Date: 2020-03-12 Impact factor: 12.310

2 in total

5 in total

Review 1. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.

Authors: Gizem Kayki-Mutlu; Zinnet Sevval Aksoyalp; Leszek Wojnowski; Martin C Michel
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2022-05-11 Impact factor: 3.195

2. The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials.

Authors: Xinyu Tao; Zeya Yan; Jiahao Meng; Wei Wang; Qiling Dai; Qiufeng Zhou; Zhifeng Wang; Zhong Wang
Journal: J Headache Pain Date: 2022-01-29 Impact factor: 7.277

Review 3. Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations.

Authors: Fred Cohen; Hsiangkuo Yuan
Journal: Ther Clin Risk Manag Date: 2022-04-22 Impact factor: 2.755

4. Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety.

Authors: Simona Lattanzi; Eugen Trinka; Claudia Altamura; Cinzia Del Giovane; Mauro Silvestrini; Francesco Brigo; Fabrizio Vernieri
Journal: Neurol Ther Date: 2022-06-15

Review 5. The Latest FDA-Approved Pharmaceuticals Containing Fragments of Tailor-Made Amino Acids and Fluorine.

Authors: Qian Wang; Jianlin Han; Alexander Sorochinsky; Aitor Landa; Greg Butler; Vadim A Soloshonok
Journal: Pharmaceuticals (Basel) Date: 2022-08-14

5 in total